SlideShare a Scribd company logo
Mujeeb Sheikh
Kidney in CV disease
 Cardiorenal overlap
 CKD is important independent predictor of mortality
  in patients with CAD (BERRY trial)
 Even in absence of CV risk factors, pts with renal
  insufficiency have elevated risk of CV disease
 Mild elevation in CR(>1.5mg/dl) are associated with
  development of CV events
 Microalbuminuria is independent risk factor for CV
  events, with RR higher than serum Cr ( 1.59 vs. 1.40)
       Hall Wo et al Am J Med Sci ,1999
       Mann JF et al, Ann Intern Med 2001
Kidney in CV disease
 Acute Renal failure
    Contrast induced nephropathy(CIN)
    Postbypass ARF
 CIN is now the 3rd leading cause of in-hospital ARF*
 CIN in patients with PCI
    Poor procedural success
    Longer hospital stay and increased mortality




  * Nash et al , Am J kidney Dis ,2002;39:930
BASIC PRINCIPLES OF CONTRAST MEDIA
Contrast Media classification
Contrast media used in Cath Lab
Contrast Pharmacology
 Contrast sole function is to attenuate X-ray
 Radio-opacification achieved by given volume of
  contrast is function of iodine concentration
 Rough estimate : 125 ml contrast = 500ml of plasma
  volume expansion
 Excreted by kidney exclusively
 Anticoagulant and antiplatelet effect of CM has no
  clinical relevance
Side effects of contrast
 Allergic reaction
      Non IgE mediated
      Ionic>Nonionic,(0.27%, SCAI registry)
     Ioxoglate (Hexabrix) significantly higher allergic reaction as
  compared to Iopamidol (Isovue) *

 Cardiovascular
         Electrophysiological
                      Heart blocks
                      Arrhythmias
          Hemodynamic
                   Vasodilatation (hypotension)
                   Increased volume overload

   * Gertz et al, JACC,1992;19:899-906
Pathophysiology of CIN
Contrast Media Induce Medullary Hypoxia

                           A temporary increase in renal transport work
                             in the thick ascending limb of Henle's loop
                                               ( in oxygen consumption)
                                       +
   Constriction of medullary capillaries ( in medullary oxygen delivery)

                                               LEAD TO

                                                  MEDULLARY ANGINA




                                Solomon, et al. Kidney Int 1998; 230-242
CI-AKI or CIN
Definition:
 New onset acute kidney injury (absolute Cr rise 0.5 mg- 1
  mg/dl or relative, 25%-50% from baseline) after contrast
  administration and in the absence of other etiology

Time course of CI-AKI:
 Occurs after 24-48 hrs of contrast
 Cr peaks in 3-5days and normalizes in 7-10 days(70%)
 In 30%, 3 weeks to return baseline or progress to CKD
 Predominantly non-oliguric AKI and with mild proteinuria
Epidemiological Issues
 Small numbers – not mega RCT
 Varying treatments used
    Differing hydration regimens
 Varying definitions
    Outcomes vary by definitions
 How much of CIN is due to contrast?
    Atheroembolism, hemodynamics
    Cause and effect???
CIN definition in clinical trials
CIN-definition
McCullough PA, Am J Med 1997
Incidence
 Incidence ranges from 1%-35%


 Low risk population incidence is 1.5%


 Mayo retrospective series evaluated 7852 pts. who had
 undergone cath /PCI found an incidence of 3.3% *
   ARF defined as 0.5 mg/dl
   Baseline Cr was predictor

    * Rihal CS et al, Circulation 2002
RISK FACTORS
Non modifiable   Modifiable
 CKD             Volume depletion
 DM              Volume of contrast
 Age(>75yr)      Multiple injection of contrast
 Class IV CHF     within 72 hrs
 Renal tx        Intraarterial vs. intravenous ?
                  High osmolal contrast (Not
                   used anymore)
CIN and High risk groups
 Baseline Cr < 2.0 mg/dl, diabetic patients had higher
  risk of ARF than nondiabetic pts
   Cr < 1.1(risk 3.7 % vs 2.0%, p=0.05)
   Cr 1.2-1.9(risk 4.5% vs 1.9%, p<0.001)
 Baseline Cr > 2.0 mg/dl, risk high regardless of
  diabetes status
   Cr. 2.0-2.9 mg/dl, risk 22.4%
   Cr > 3 mg/dl, risk 30.6%
Predictors of ARF requiring dialysis
after PCI

                                             Mean contrast vol
                                             250cc,(Cath+ PCI)
                                             Mean age 65yrs




 Predictors of CIN Crcl >DM> contrast dose
OUTCOMES OF CIN
CIN & Mortality
 Retrospective case control
  study of 16,248 hospitalized
  patients who received
  contrast
 Cases with CIN(n=183)
  matched with controls(n=174)
    Matched for baseline
     creatinine
    APACHE score

   Levy EM,JAMA 1995
CIN after PCI & Mortality
Derivation-validation
method in 1800 patiens
Incidence of CIN 14% and
  ARF requiring HD was
7.7%
Multivariate predictors:
CrCl, diabetes and contrast
dose
No case of CIN in patients
with contrast dose of <
100ml




    McCullough PA et al, Am J Med,1997
Clinical outcomes of CIN patients
requiring HD after PCI
                                     Long-term outcome




   Gruberg L et al Cath Cardiovasc Interv, 2001
Long term outcome of CIN
 Mayo retrospective series
  evaluated 7852 pts. who had
  undergone cath /PCI found
  an incidence of 3.3%
    ARF defined as 0.5 mg/dl
    CIN was related to baseline
     serum Cr and diabetes




        Rihal CS et al Circ 2002
Prognostic implications of CIN
following PCI in pts with CKD
 439 pts with baseline serum cr. > 1.8
 All well hydrated, all received non ionic dye
 161 pts(37%) had increase in serum cr > 25%
      and 278(63%) did not
CIN prognosis after PCI in CKD
In hospital outcome                    One year outcome
          No Cr Rise   25% Cr                        No Cr Rise   25% Cr
       P<0.001         P<0.001 28.7%
30%                                    50%    P<0.001
                                       40%       37.7%                  P=NS
20%                      15.9%
                                                            P=NS
               14.9%                   30%                           23.6%
                                                                          21.4%
                                             19.4%
                                       20%                   13.4%
10%                                                      12.4%
        4.9%
                                       10%
 0%                                     0%
          Death           Non-Q MI            Death         MI         TLR




      Gruberg et al JACC, 2000
CIN and long term mortality




 Gruberg et al, 2000
Predicting CIN
 Developmental data
  set(n=8752)
 Validation data
  set(n=2786)
 Multivariate logistic
  regression to identify
  variables, p<0.0001
 C statistics 0.67



Mehran et al JACC,2000
RISK SCORE
CIN risk score & HD
CIN and I yr Mortality
PREVENTING CONTRAST INDUCED
        NEPHROPATHY
CIN Prevention(literature review)
                                                   35
                                                   randomized
                                                   control trial



   56 review
   articles&
   comments




 No FDA approved therapy for prevention or treatment
Post intervention prevention of
CIN-AKI
 Failed agents for prevention/mitigation of contrast-
 induced nephropathy
   Calcium channel antagonists
   adenosine antagonists
   dopamine
   Mannitol
   Furosemide
   Endothelin-receptor antagonists
What is optimal hydration?




           Dal lake, Kashmir
Hydration Regimen
Hydration started at 8
am on the day of
elective cath and
continued for another
12 hrs (1ml/kg) after
cath.
Pts encouraged to
drink fluids




     Mueller et al Arch intern med ,2002
NS vs.0.45NS
Prevention of CIN with sodium
 bicarbonate
                                          Baseline Cr >1.8mg/dl
                                         Iopamidol contrast used
Regimen                                            N=137
3ml/kg bolus for 1hr
before & 1ml/kg 6hr after

                                 Sodium chloride           Sodium bicarbonate
                                      N=68                       N=69




                     Primary Endpoint was increase in serum Cr
                                      >25%


     Merten et al, JAMA2004
Results (primary endpoint)
                    Sodium        Sodium     P value
                    bicarbonate   chloride
                    (N=60)        (N=59)



 CIN %              1.7 %         13.6%      0.02




 CIN (^ 0.5mg/dl)   1.7%          11.9%      0.03
MEENA study (N=400)
N-Acetylcysteine (NAC)
 Prospective RCT
 83 high risk pts
 Cr Cl <50ml/min
 Diabetes 33%
 IV contrast CT (low
  osmolal,75ml)
 NAC 600mg BID X 2 days
 Hydration 0.45 saline at
  1ml/kg

   Tepel, NEJM 2000
NAC & PCI
 N=79
 Mean Cr 2.3mg/dl                     *APART trial n=45
 All received hydration               Mean Cr 1.6mg/dl
 NAC 600mg q12 x4 doses, before       NAC IV before PCI and 3 doses BID
 PCI                                  after PCI

                          P=NS




Caputo Am j kidney Dis, 2000      * Diaz-Sandoval et al Am J Cardiol 2002
NAC & relative risk
    META-ANALYSIS of 7 RCT




 Birke et al., Lancet 2003
Does type of contrast matter?
                                  Patients with diabetes and CKD
                                           (1.5-3.5 mg/dl)
  NEPHRIC STUDY                       Undergoing coronary
                                    angiography/Aortofemoral
                                          angiography




                   Iso-Osmolol, Nonionic
                                                           Low Osmolar, Nonionic
                       Iodixanol N=64
                                                               Iohexinol N=65
                  Mean contrast vol. 163 ml
                                                          Mean contrast vol.162 ml
                            PCI




              Randomized control trial
              Primary endpoint was CIN
             Serum Cr at 72 hrs after Cath

                                                            Aspelin ,NEJM 2003
Results
Cr (µmol),P=0.002
Renal failure in pts undergoing coronary procedures using Iso-
Osmolar or Low Osmolar CM


 Swedish coronary angiography
    and angioplasty registry
   Swedish hospital discharge
    registry
   Only included diabetic and CKD
    pts
   Only pts receiving PCI
   Also patients receiving iohexol
    fr0m 1999-2003
   Mean contrast volume:
    iodixanol: 138±89 ml vs.
    ioxaglate: 147±105 ml

Liss et al., kidney International 2006
Rehospitilization with ARF as the
primary diagnosis
Long term Results




                    * Groups differ in time period
“Adjusted” contrast dose
 Michigan Data Base- 16,592
    PCI’s
   Developmental, validation data
    set
   MRCD = 5cc X body weight
    (kg)/serum cr.
   MRCD ratio= total contrast
    vol./MRCD
   NRD(0.44 %, 0.35%),
    mortality(39%, 26%)
   Unadjusted contrast dose not a
    univariate predictor
 AJC 2002; 90: 1068-1073
Adjusted contrast dose
Take home points
 Contrast-Induced Nephropathy is a common
  complication in higher-risk patients
 Even with chemical resolution of CIN and a return of
  serum creatinine towards baseline, the 1-year mortality
  remains over 25%, making prevention mandatory in
  higher-risk patients
 High-risk characteristics include renal insufficiency
  (Cr > 1.5 mg/dL) diabetes and contrast dose
 Pathophysiology of CIN seems to involve contrast-
  induced renal medullary ischemia
Recommendations
 THANK YOU

More Related Content

What's hot

SGLT2 inhibitor trials
SGLT2 inhibitor trialsSGLT2 inhibitor trials
SGLT2 inhibitor trials
Dr. Rohan Sonawane
 
Hepatorenal syndrome
Hepatorenal syndromeHepatorenal syndrome
Hepatorenal syndromeheyraghul
 
Approach to cardio renal syndrome
Approach to cardio renal syndromeApproach to cardio renal syndrome
Approach to cardio renal syndrome
ajayyadav753
 
Novel Oral Anticoagulants (NOACs) in CKD & Dialysis Patients - How to Use? Wh...
Novel Oral Anticoagulants (NOACs) in CKD & Dialysis Patients - How to Use? Wh...Novel Oral Anticoagulants (NOACs) in CKD & Dialysis Patients - How to Use? Wh...
Novel Oral Anticoagulants (NOACs) in CKD & Dialysis Patients - How to Use? Wh...
NephroTube - Dr.Gawad
 
Contrast induced nephropathy
Contrast  induced nephropathyContrast  induced nephropathy
Contrast induced nephropathy
mohamed hassan abbass
 
HTN in Hemodialysis Patients - A Clinical Approach of Management - Dr. Gawad
HTN in Hemodialysis Patients - A Clinical Approach of Management - Dr. GawadHTN in Hemodialysis Patients - A Clinical Approach of Management - Dr. Gawad
HTN in Hemodialysis Patients - A Clinical Approach of Management - Dr. Gawad
NephroTube - Dr.Gawad
 
Cardio renal-syndrome
Cardio renal-syndromeCardio renal-syndrome
Cardio renal-syndrome
raj shekar
 
RENAL DENERAVTION IN HTN
RENAL DENERAVTION IN HTNRENAL DENERAVTION IN HTN
RENAL DENERAVTION IN HTN
Anand Manjunath
 
Esc 2020 guidelines for the management of acute coronary
Esc 2020 guidelines for the management of acute coronaryEsc 2020 guidelines for the management of acute coronary
Esc 2020 guidelines for the management of acute coronary
Himanshu Rana
 
New day in heart failure
New day in heart failureNew day in heart failure
New day in heart failure
Waseem Omar
 
Contrast-induced nephropathy.pptx
Contrast-induced nephropathy.pptxContrast-induced nephropathy.pptx
Contrast-induced nephropathy.pptx
Yogesh Shilimkar
 
Hemodialysis Anticoagulation - Different Protocols / Protocol Selection - Dr....
Hemodialysis Anticoagulation - Different Protocols / Protocol Selection - Dr....Hemodialysis Anticoagulation - Different Protocols / Protocol Selection - Dr....
Hemodialysis Anticoagulation - Different Protocols / Protocol Selection - Dr....
NephroTube - Dr.Gawad
 
Cardiovascular complications in CKD - Dr. Mohamed Mamdouh AbdAlBary
Cardiovascular complications in CKD - Dr. Mohamed Mamdouh AbdAlBaryCardiovascular complications in CKD - Dr. Mohamed Mamdouh AbdAlBary
Cardiovascular complications in CKD - Dr. Mohamed Mamdouh AbdAlBary
MNDU net
 
Contrast Induced Nephropathy
Contrast Induced NephropathyContrast Induced Nephropathy
Contrast Induced Nephropathy
Ramachandra Barik
 
SGLT2 inhibitors in Heart failure: A prized addition to HF treatment options
SGLT2 inhibitors in Heart failure: A prized addition to HF treatment optionsSGLT2 inhibitors in Heart failure: A prized addition to HF treatment options
SGLT2 inhibitors in Heart failure: A prized addition to HF treatment options
ahvc0858
 
Hypokalemia (Practical Approach) - Dr. Gawad
Hypokalemia (Practical Approach) - Dr. GawadHypokalemia (Practical Approach) - Dr. Gawad
Hypokalemia (Practical Approach) - Dr. Gawad
NephroTube - Dr.Gawad
 
What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“
Arindam Pande
 
IntraDialytic Hypertension (Basic Science → Evidence → Practice) - Dr. Gawad
IntraDialytic Hypertension (Basic Science → Evidence → Practice) - Dr. GawadIntraDialytic Hypertension (Basic Science → Evidence → Practice) - Dr. Gawad
IntraDialytic Hypertension (Basic Science → Evidence → Practice) - Dr. Gawad
NephroTube - Dr.Gawad
 
Pci vs cabg
Pci vs cabg    Pci vs cabg
Pci vs cabg
DR. VINIT KUMAR
 

What's hot (20)

SGLT2 inhibitor trials
SGLT2 inhibitor trialsSGLT2 inhibitor trials
SGLT2 inhibitor trials
 
Hepatorenal syndrome
Hepatorenal syndromeHepatorenal syndrome
Hepatorenal syndrome
 
Approach to cardio renal syndrome
Approach to cardio renal syndromeApproach to cardio renal syndrome
Approach to cardio renal syndrome
 
Novel Oral Anticoagulants (NOACs) in CKD & Dialysis Patients - How to Use? Wh...
Novel Oral Anticoagulants (NOACs) in CKD & Dialysis Patients - How to Use? Wh...Novel Oral Anticoagulants (NOACs) in CKD & Dialysis Patients - How to Use? Wh...
Novel Oral Anticoagulants (NOACs) in CKD & Dialysis Patients - How to Use? Wh...
 
Contrast induced nephropathy
Contrast  induced nephropathyContrast  induced nephropathy
Contrast induced nephropathy
 
HTN in Hemodialysis Patients - A Clinical Approach of Management - Dr. Gawad
HTN in Hemodialysis Patients - A Clinical Approach of Management - Dr. GawadHTN in Hemodialysis Patients - A Clinical Approach of Management - Dr. Gawad
HTN in Hemodialysis Patients - A Clinical Approach of Management - Dr. Gawad
 
Cardio renal-syndrome
Cardio renal-syndromeCardio renal-syndrome
Cardio renal-syndrome
 
RENAL DENERAVTION IN HTN
RENAL DENERAVTION IN HTNRENAL DENERAVTION IN HTN
RENAL DENERAVTION IN HTN
 
Esc 2020 guidelines for the management of acute coronary
Esc 2020 guidelines for the management of acute coronaryEsc 2020 guidelines for the management of acute coronary
Esc 2020 guidelines for the management of acute coronary
 
New day in heart failure
New day in heart failureNew day in heart failure
New day in heart failure
 
Contrast-induced nephropathy.pptx
Contrast-induced nephropathy.pptxContrast-induced nephropathy.pptx
Contrast-induced nephropathy.pptx
 
Hemodialysis Anticoagulation - Different Protocols / Protocol Selection - Dr....
Hemodialysis Anticoagulation - Different Protocols / Protocol Selection - Dr....Hemodialysis Anticoagulation - Different Protocols / Protocol Selection - Dr....
Hemodialysis Anticoagulation - Different Protocols / Protocol Selection - Dr....
 
Cardiovascular complications in CKD - Dr. Mohamed Mamdouh AbdAlBary
Cardiovascular complications in CKD - Dr. Mohamed Mamdouh AbdAlBaryCardiovascular complications in CKD - Dr. Mohamed Mamdouh AbdAlBary
Cardiovascular complications in CKD - Dr. Mohamed Mamdouh AbdAlBary
 
Contrast Induced Nephropathy
Contrast Induced NephropathyContrast Induced Nephropathy
Contrast Induced Nephropathy
 
SGLT2 inhibitors in Heart failure: A prized addition to HF treatment options
SGLT2 inhibitors in Heart failure: A prized addition to HF treatment optionsSGLT2 inhibitors in Heart failure: A prized addition to HF treatment options
SGLT2 inhibitors in Heart failure: A prized addition to HF treatment options
 
Hypokalemia (Practical Approach) - Dr. Gawad
Hypokalemia (Practical Approach) - Dr. GawadHypokalemia (Practical Approach) - Dr. Gawad
Hypokalemia (Practical Approach) - Dr. Gawad
 
Diuretics in CKD
Diuretics in CKDDiuretics in CKD
Diuretics in CKD
 
What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“
 
IntraDialytic Hypertension (Basic Science → Evidence → Practice) - Dr. Gawad
IntraDialytic Hypertension (Basic Science → Evidence → Practice) - Dr. GawadIntraDialytic Hypertension (Basic Science → Evidence → Practice) - Dr. Gawad
IntraDialytic Hypertension (Basic Science → Evidence → Practice) - Dr. Gawad
 
Pci vs cabg
Pci vs cabg    Pci vs cabg
Pci vs cabg
 

Similar to Contrast induced-Acute Kidney Injury

Hussein drug therapy in aki 3 osama alshahat 2 pptx
Hussein drug therapy in aki 3 osama alshahat 2 pptxHussein drug therapy in aki 3 osama alshahat 2 pptx
Hussein drug therapy in aki 3 osama alshahat 2 pptx
FarragBahbah
 
O Que Mudou no Tratamento da Lesão Renal Aguda nos úLtimos 10 Anos
O Que Mudou no Tratamento da Lesão Renal Aguda nos úLtimos 10 AnosO Que Mudou no Tratamento da Lesão Renal Aguda nos úLtimos 10 Anos
O Que Mudou no Tratamento da Lesão Renal Aguda nos úLtimos 10 AnosFederal University of Bahia
 
contrast nephropathy
contrast nephropathycontrast nephropathy
contrast nephropathySurendra Babu
 
Ticagrelor PROPERTIES AND TRIALS
Ticagrelor PROPERTIES AND TRIALSTicagrelor PROPERTIES AND TRIALS
Ticagrelor PROPERTIES AND TRIALS
AdnanAliKhan34
 
Hydration for contrast induced nephropathy
Hydration for contrast induced nephropathyHydration for contrast induced nephropathy
Hydration for contrast induced nephropathy
Wisit Cheungpasitporn
 
A New Perspective on Acute Kidney Injury
A New Perspective on Acute Kidney InjuryA New Perspective on Acute Kidney Injury
A New Perspective on Acute Kidney Injurystevechendoc
 
Highlights aha 2016
Highlights aha 2016Highlights aha 2016
Highlights aha 2016
Shathiskumar Govindaraju
 
AKII.pptx
AKII.pptxAKII.pptx
AKII.pptx
ssuser6aa7a3
 
Effect Of Remote Ischemic Preconditioning On AKI Among.pptx
Effect Of Remote Ischemic Preconditioning On AKI Among.pptxEffect Of Remote Ischemic Preconditioning On AKI Among.pptx
Effect Of Remote Ischemic Preconditioning On AKI Among.pptx
NayyarSaleem2
 
Intensive care nephrology
Intensive care nephrologyIntensive care nephrology
Intensive care nephrology
FarragBahbah
 
Managing Diabetic Thrombocytopathy: Focussing on OAPS
Managing Diabetic Thrombocytopathy:   Focussing on OAPSManaging Diabetic Thrombocytopathy:   Focussing on OAPS
Managing Diabetic Thrombocytopathy: Focussing on OAPS
srisrihoistic hospital
 
Rosuvastatina disminuye la incidencia de nefropatía por contraste en paciente...
Rosuvastatina disminuye la incidencia de nefropatía por contraste en paciente...Rosuvastatina disminuye la incidencia de nefropatía por contraste en paciente...
Rosuvastatina disminuye la incidencia de nefropatía por contraste en paciente...
Sociedad Latinoamericana de Cardiología Intervencionista
 
Emergency medicine research
Emergency medicine researchEmergency medicine research
Emergency medicine research
tbf413
 
the po
the pothe po
the po
SoM
 
Nefropatia inducida por medio de contraste 2015
Nefropatia inducida por medio de contraste 2015Nefropatia inducida por medio de contraste 2015
Nefropatia inducida por medio de contraste 2015
Cristhian Bueno Lara
 
Anginal pectoris refractory to standard medical therapy i
Anginal pectoris refractory to standard medical therapy iAnginal pectoris refractory to standard medical therapy i
Anginal pectoris refractory to standard medical therapy iBALASUBRAMANIAM IYER
 
Heart Failure By Dr. UC Samal
Heart Failure By Dr. UC SamalHeart Failure By Dr. UC Samal
Heart Failure By Dr. UC Samal
drucsamal
 

Similar to Contrast induced-Acute Kidney Injury (20)

Hussein drug therapy in aki 3 osama alshahat 2 pptx
Hussein drug therapy in aki 3 osama alshahat 2 pptxHussein drug therapy in aki 3 osama alshahat 2 pptx
Hussein drug therapy in aki 3 osama alshahat 2 pptx
 
O Que Mudou no Tratamento da Lesão Renal Aguda nos úLtimos 10 Anos
O Que Mudou no Tratamento da Lesão Renal Aguda nos úLtimos 10 AnosO Que Mudou no Tratamento da Lesão Renal Aguda nos úLtimos 10 Anos
O Que Mudou no Tratamento da Lesão Renal Aguda nos úLtimos 10 Anos
 
contrast nephropathy
contrast nephropathycontrast nephropathy
contrast nephropathy
 
Ticagrelor PROPERTIES AND TRIALS
Ticagrelor PROPERTIES AND TRIALSTicagrelor PROPERTIES AND TRIALS
Ticagrelor PROPERTIES AND TRIALS
 
Hydration for contrast induced nephropathy
Hydration for contrast induced nephropathyHydration for contrast induced nephropathy
Hydration for contrast induced nephropathy
 
Aha lbct
Aha lbctAha lbct
Aha lbct
 
AHA: LBCT
AHA: LBCTAHA: LBCT
AHA: LBCT
 
A New Perspective on Acute Kidney Injury
A New Perspective on Acute Kidney InjuryA New Perspective on Acute Kidney Injury
A New Perspective on Acute Kidney Injury
 
Highlights aha 2016
Highlights aha 2016Highlights aha 2016
Highlights aha 2016
 
AKII.pptx
AKII.pptxAKII.pptx
AKII.pptx
 
Effect Of Remote Ischemic Preconditioning On AKI Among.pptx
Effect Of Remote Ischemic Preconditioning On AKI Among.pptxEffect Of Remote Ischemic Preconditioning On AKI Among.pptx
Effect Of Remote Ischemic Preconditioning On AKI Among.pptx
 
Intensive care nephrology
Intensive care nephrologyIntensive care nephrology
Intensive care nephrology
 
Managing Diabetic Thrombocytopathy: Focussing on OAPS
Managing Diabetic Thrombocytopathy:   Focussing on OAPSManaging Diabetic Thrombocytopathy:   Focussing on OAPS
Managing Diabetic Thrombocytopathy: Focussing on OAPS
 
Randil
RandilRandil
Randil
 
Rosuvastatina disminuye la incidencia de nefropatía por contraste en paciente...
Rosuvastatina disminuye la incidencia de nefropatía por contraste en paciente...Rosuvastatina disminuye la incidencia de nefropatía por contraste en paciente...
Rosuvastatina disminuye la incidencia de nefropatía por contraste en paciente...
 
Emergency medicine research
Emergency medicine researchEmergency medicine research
Emergency medicine research
 
the po
the pothe po
the po
 
Nefropatia inducida por medio de contraste 2015
Nefropatia inducida por medio de contraste 2015Nefropatia inducida por medio de contraste 2015
Nefropatia inducida por medio de contraste 2015
 
Anginal pectoris refractory to standard medical therapy i
Anginal pectoris refractory to standard medical therapy iAnginal pectoris refractory to standard medical therapy i
Anginal pectoris refractory to standard medical therapy i
 
Heart Failure By Dr. UC Samal
Heart Failure By Dr. UC SamalHeart Failure By Dr. UC Samal
Heart Failure By Dr. UC Samal
 

Recently uploaded

Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXXPhrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
MIRIAMSALINAS13
 
Chapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptxChapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptx
Mohd Adib Abd Muin, Senior Lecturer at Universiti Utara Malaysia
 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
Jisc
 
Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
Jisc
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
timhan337
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
Special education needs
 
Embracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic ImperativeEmbracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic Imperative
Peter Windle
 
678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf
CarlosHernanMontoyab2
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
siemaillard
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
Jean Carlos Nunes Paixão
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
camakaiclarkmusic
 
"Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe..."Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe...
SACHIN R KONDAGURI
 
Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
beazzy04
 
How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...
Jisc
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
Delapenabediema
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
TechSoup
 
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCECLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
BhavyaRajput3
 
1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx
JosvitaDsouza2
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
Celine George
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
DeeptiGupta154
 

Recently uploaded (20)

Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXXPhrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
 
Chapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptxChapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptx
 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
 
Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
 
Embracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic ImperativeEmbracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic Imperative
 
678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
 
"Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe..."Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe...
 
Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
 
How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
 
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCECLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
 
1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
 

Contrast induced-Acute Kidney Injury

  • 2. Kidney in CV disease  Cardiorenal overlap  CKD is important independent predictor of mortality in patients with CAD (BERRY trial)  Even in absence of CV risk factors, pts with renal insufficiency have elevated risk of CV disease  Mild elevation in CR(>1.5mg/dl) are associated with development of CV events  Microalbuminuria is independent risk factor for CV events, with RR higher than serum Cr ( 1.59 vs. 1.40) Hall Wo et al Am J Med Sci ,1999 Mann JF et al, Ann Intern Med 2001
  • 3. Kidney in CV disease  Acute Renal failure  Contrast induced nephropathy(CIN)  Postbypass ARF  CIN is now the 3rd leading cause of in-hospital ARF*  CIN in patients with PCI  Poor procedural success  Longer hospital stay and increased mortality * Nash et al , Am J kidney Dis ,2002;39:930
  • 4. BASIC PRINCIPLES OF CONTRAST MEDIA
  • 6. Contrast media used in Cath Lab
  • 7. Contrast Pharmacology  Contrast sole function is to attenuate X-ray  Radio-opacification achieved by given volume of contrast is function of iodine concentration  Rough estimate : 125 ml contrast = 500ml of plasma volume expansion  Excreted by kidney exclusively  Anticoagulant and antiplatelet effect of CM has no clinical relevance
  • 8. Side effects of contrast  Allergic reaction Non IgE mediated Ionic>Nonionic,(0.27%, SCAI registry) Ioxoglate (Hexabrix) significantly higher allergic reaction as compared to Iopamidol (Isovue) *  Cardiovascular Electrophysiological Heart blocks Arrhythmias Hemodynamic Vasodilatation (hypotension) Increased volume overload * Gertz et al, JACC,1992;19:899-906
  • 10. Contrast Media Induce Medullary Hypoxia A temporary increase in renal transport work in the thick ascending limb of Henle's loop ( in oxygen consumption) + Constriction of medullary capillaries ( in medullary oxygen delivery) LEAD TO MEDULLARY ANGINA Solomon, et al. Kidney Int 1998; 230-242
  • 11. CI-AKI or CIN Definition:  New onset acute kidney injury (absolute Cr rise 0.5 mg- 1 mg/dl or relative, 25%-50% from baseline) after contrast administration and in the absence of other etiology Time course of CI-AKI:  Occurs after 24-48 hrs of contrast  Cr peaks in 3-5days and normalizes in 7-10 days(70%)  In 30%, 3 weeks to return baseline or progress to CKD  Predominantly non-oliguric AKI and with mild proteinuria
  • 12. Epidemiological Issues  Small numbers – not mega RCT  Varying treatments used  Differing hydration regimens  Varying definitions  Outcomes vary by definitions  How much of CIN is due to contrast?  Atheroembolism, hemodynamics  Cause and effect???
  • 13. CIN definition in clinical trials
  • 15. McCullough PA, Am J Med 1997
  • 16. Incidence  Incidence ranges from 1%-35%  Low risk population incidence is 1.5%  Mayo retrospective series evaluated 7852 pts. who had undergone cath /PCI found an incidence of 3.3% *  ARF defined as 0.5 mg/dl  Baseline Cr was predictor * Rihal CS et al, Circulation 2002
  • 17. RISK FACTORS Non modifiable Modifiable  CKD  Volume depletion  DM  Volume of contrast  Age(>75yr)  Multiple injection of contrast  Class IV CHF within 72 hrs  Renal tx  Intraarterial vs. intravenous ?  High osmolal contrast (Not used anymore)
  • 18. CIN and High risk groups  Baseline Cr < 2.0 mg/dl, diabetic patients had higher risk of ARF than nondiabetic pts  Cr < 1.1(risk 3.7 % vs 2.0%, p=0.05)  Cr 1.2-1.9(risk 4.5% vs 1.9%, p<0.001)  Baseline Cr > 2.0 mg/dl, risk high regardless of diabetes status  Cr. 2.0-2.9 mg/dl, risk 22.4%  Cr > 3 mg/dl, risk 30.6%
  • 19. Predictors of ARF requiring dialysis after PCI Mean contrast vol 250cc,(Cath+ PCI) Mean age 65yrs Predictors of CIN Crcl >DM> contrast dose
  • 21. CIN & Mortality  Retrospective case control study of 16,248 hospitalized patients who received contrast  Cases with CIN(n=183) matched with controls(n=174)  Matched for baseline creatinine  APACHE score Levy EM,JAMA 1995
  • 22. CIN after PCI & Mortality Derivation-validation method in 1800 patiens Incidence of CIN 14% and ARF requiring HD was 7.7% Multivariate predictors: CrCl, diabetes and contrast dose No case of CIN in patients with contrast dose of < 100ml McCullough PA et al, Am J Med,1997
  • 23. Clinical outcomes of CIN patients requiring HD after PCI Long-term outcome Gruberg L et al Cath Cardiovasc Interv, 2001
  • 24. Long term outcome of CIN  Mayo retrospective series evaluated 7852 pts. who had undergone cath /PCI found an incidence of 3.3%  ARF defined as 0.5 mg/dl  CIN was related to baseline serum Cr and diabetes Rihal CS et al Circ 2002
  • 25. Prognostic implications of CIN following PCI in pts with CKD  439 pts with baseline serum cr. > 1.8  All well hydrated, all received non ionic dye  161 pts(37%) had increase in serum cr > 25% and 278(63%) did not
  • 26. CIN prognosis after PCI in CKD In hospital outcome One year outcome No Cr Rise 25% Cr No Cr Rise 25% Cr P<0.001 P<0.001 28.7% 30% 50% P<0.001 40% 37.7% P=NS 20% 15.9% P=NS 14.9% 30% 23.6% 21.4% 19.4% 20% 13.4% 10% 12.4% 4.9% 10% 0% 0% Death Non-Q MI Death MI TLR Gruberg et al JACC, 2000
  • 27. CIN and long term mortality Gruberg et al, 2000
  • 28. Predicting CIN  Developmental data set(n=8752)  Validation data set(n=2786)  Multivariate logistic regression to identify variables, p<0.0001  C statistics 0.67 Mehran et al JACC,2000
  • 31. CIN and I yr Mortality
  • 33. CIN Prevention(literature review) 35 randomized control trial 56 review articles& comments No FDA approved therapy for prevention or treatment
  • 34. Post intervention prevention of CIN-AKI  Failed agents for prevention/mitigation of contrast- induced nephropathy  Calcium channel antagonists  adenosine antagonists  dopamine  Mannitol  Furosemide  Endothelin-receptor antagonists
  • 35. What is optimal hydration? Dal lake, Kashmir
  • 36. Hydration Regimen Hydration started at 8 am on the day of elective cath and continued for another 12 hrs (1ml/kg) after cath. Pts encouraged to drink fluids Mueller et al Arch intern med ,2002
  • 37.
  • 39. Prevention of CIN with sodium bicarbonate Baseline Cr >1.8mg/dl Iopamidol contrast used Regimen N=137 3ml/kg bolus for 1hr before & 1ml/kg 6hr after Sodium chloride Sodium bicarbonate N=68 N=69 Primary Endpoint was increase in serum Cr >25% Merten et al, JAMA2004
  • 40. Results (primary endpoint) Sodium Sodium P value bicarbonate chloride (N=60) (N=59) CIN % 1.7 % 13.6% 0.02 CIN (^ 0.5mg/dl) 1.7% 11.9% 0.03
  • 42. N-Acetylcysteine (NAC)  Prospective RCT  83 high risk pts  Cr Cl <50ml/min  Diabetes 33%  IV contrast CT (low osmolal,75ml)  NAC 600mg BID X 2 days  Hydration 0.45 saline at 1ml/kg Tepel, NEJM 2000
  • 43. NAC & PCI N=79 Mean Cr 2.3mg/dl *APART trial n=45 All received hydration Mean Cr 1.6mg/dl NAC 600mg q12 x4 doses, before NAC IV before PCI and 3 doses BID PCI after PCI P=NS Caputo Am j kidney Dis, 2000 * Diaz-Sandoval et al Am J Cardiol 2002
  • 44. NAC & relative risk META-ANALYSIS of 7 RCT Birke et al., Lancet 2003
  • 45. Does type of contrast matter? Patients with diabetes and CKD (1.5-3.5 mg/dl) NEPHRIC STUDY Undergoing coronary angiography/Aortofemoral angiography Iso-Osmolol, Nonionic Low Osmolar, Nonionic Iodixanol N=64 Iohexinol N=65 Mean contrast vol. 163 ml Mean contrast vol.162 ml PCI Randomized control trial Primary endpoint was CIN Serum Cr at 72 hrs after Cath Aspelin ,NEJM 2003
  • 47. Renal failure in pts undergoing coronary procedures using Iso- Osmolar or Low Osmolar CM  Swedish coronary angiography and angioplasty registry  Swedish hospital discharge registry  Only included diabetic and CKD pts  Only pts receiving PCI  Also patients receiving iohexol fr0m 1999-2003  Mean contrast volume: iodixanol: 138±89 ml vs. ioxaglate: 147±105 ml Liss et al., kidney International 2006
  • 48. Rehospitilization with ARF as the primary diagnosis
  • 49. Long term Results * Groups differ in time period
  • 50. “Adjusted” contrast dose  Michigan Data Base- 16,592 PCI’s  Developmental, validation data set  MRCD = 5cc X body weight (kg)/serum cr.  MRCD ratio= total contrast vol./MRCD  NRD(0.44 %, 0.35%), mortality(39%, 26%)  Unadjusted contrast dose not a univariate predictor  AJC 2002; 90: 1068-1073
  • 52. Take home points  Contrast-Induced Nephropathy is a common complication in higher-risk patients  Even with chemical resolution of CIN and a return of serum creatinine towards baseline, the 1-year mortality remains over 25%, making prevention mandatory in higher-risk patients  High-risk characteristics include renal insufficiency (Cr > 1.5 mg/dL) diabetes and contrast dose  Pathophysiology of CIN seems to involve contrast- induced renal medullary ischemia

Editor's Notes

  1. Rct have not founf thesehematoligical effects due to cocncomitant use of antiplatelet and anticoaugs
  2. Osmoality dependent lead to release of adenosine
  3. To compare similar degrees of injury regardless of the baseline serum level, the relative change in serum creatinine is a preferable metric (Table 2b). With a relative change definition, all patients lose the same percentage of renal function regardless of the level of renal function at baseline. There is still a bias, however, for a smaller absolute loss of GFR to satisfy the definition of CIN when there is a lower GFR at baseline. Finally, it follows from the above discussion that in patients with milder degrees of renal insufficiency (creatinine less than 2 mg/dl), the incidence of CIN will always be less when a 0.5 mg/dl absolute increase is used as a definition compared to a 25% increase in serum creatinine. A greater loss of GFR is necessary to satisfy the definition of CIN when the absolute change in serum creatinine is used (Table 2a vs b).Which definition, absolute or relative increase in serum creatinine, reflects outcomes the best? Gruberget al.1 correlated outcomes following contrast exposure in patients who underwent cardiac catheterization. A worse outcome (at 1 year) was found in those
  4. Peterm Mc cullough
  5. There is no question that ccin lead to increased mortalityThis is the data from aretropective study of more than 16k pts who received contrast for any radiological procedure Odds of dying was 5 times high if cinoccured
  6. How about CIN after PCI Ina study by peter mccollough the risk of inhospital mortality wasignificanlty higher in pts who had arf after pci and it was higher if they needed dialysis comapred to very low risk with no CIN
  7. Thirty-one patients required hemodialysis during hospitalization.Their in-hospital mortality was 22.6%. Fourpatients were discharged on chronic dialysis. The cumulativeone-year mortality was significantly higher in patientswith renal function deterioration (37.7% vs. 19.4%, p 50.001, Table 5 and Fig. 2)—35.4% for those who did notrequire dialysis and 45.2% for those who required dialysis.Of the 17 patients who required in-hospital dialysis andwho were alive at one year, 3 required chronic dialysis.When the one-year mortality was compared with regardto the percent increase in creatinine, there was a noticeabledifference in patients with a 25% increase or greater (Fig. 3).Myocardial infarction and revascularization events weresimilar in both groupsAcute deterioration in renal function is a recognized complication after coronary angiographyand intervention.OBJECTIVES The goal of this study was to determine the impact on acute and long-term mortality andmorbidity of contrast-induced deterioration in renal function after coronary intervention.METHODS We studied 439 consecutive patients who had a baseline serum creatinine $1.8 mg/dL(159.1 mmol/L) who were not on dialysis who underwent percutaneous coronary interventionin a tertiary referral center. All patients were hydrated before the procedure, and almost allreceived ioxaglatemeglumine; 161 (37%) patients had an increase in serum creatinine $25%within 48 h or required dialysis and 278 (63%) did not. In-hospital and out-of-hospitalclinical events (death, myocardial infarction, repeat revascularization) were assessed by sourcedocumentation.RESULTS Independent predictors of renal function deterioration were left ventricular ejection fraction(p 5 0.02) and contrast volume (p 5 0.01). In-hospital mortality was 14.9% for patients withfurther renal function deterioration versus 4.9% for patients with no creatinine increase (p 50.001); other complications were also more frequent. Thirty-one patients required hemodialysis;their in-hospital mortality was 22.6%. Four patients were discharged on chronicdialysis. The cumulative one-year mortality was 45.2% for those who required dialysis, 35.4%for those who did not require dialysis and 19.4% for patients with no creatinine increase (p 50.001). Independent predictors of one-year mortality were creatinine elevation (p 5 0.0001),age (p 5 0.03) and vein graft lesion location (p 5 0.08).CONCLUSIONS For patients with pre-existing renal insufficiency, renal function deterioration after coronaryintervention is a marker for poor outcomes. This is especially true for patients who requiredialysis. (J Am CollCardiol 2000;36:1542– 8) © 2000 by the American College ofCardiologyAcute deterioration in renal function is a recognized complicationafter coronary angiography, particularly for patientswith pre-existing chronic renal insufficiency (CRI)(1– 4). Previous studies have shown that 12 to 14% ofpatients who develop acute renal insufficiency during hospitalizationdo so after procedures involving radiographiccontrast (5,6). For patients with abnormal baseline renalfunction, the incidence of progressive deterioration can be ashigh as 42% (1,7). For hospitalized, critically ill patients,this carries a poor prognosis, especially if dialysis becomesnecessary (5–10).The expanding use of diagnostic and therapeutic percutaneousinterventions makes it important to understand thepotential risks
  8. Based on risk score you see that there is linear and exponential increase in the incidenc of CINFrom 7.5 to 14 to 16 and 57
  9. They also found that this score predicted need for inhospital dialysis and higher score were significantly associated with need for hd
  10. Prognostic significance of the score and higher score had higher one yr mortality
  11. I am not good at drawing
  12. This is alist of ailed therapies thathave been tried and they should no longer be used infact some of these therapies can cause harmHypothesis discusss
  13. Interestingly you see that pts with 0.9 hydration had less cin as compared to .45When you can hydrate the pt.
  14. Trial terminated earlierHad not presecified the the P and P0.02Alpha errorNonetheless it was positive trial and a s you know law of nature is for every pos trail there is one negative trial
  15. Study in pts not undergoing cath or pci
  16. Barrettecarlisle radiology1993
  17. To convert into a dichotomous variable they used mrcd ratioAsmrcd is a continous variable and can’t comape